Ron Peck, MD, CMO of Arvinas @Arvinas on the orally-active proteolysis targeting chimera (PROTAC) molecule being developed to treat men with metastatic prostate cancer, and ARV-471, a potential treatment for patients with locally advanced or metastatic breast cancer.
The results of both trials showed a favorable overall safety profile, and exposures reaching levels predicted by preclinical studies to be efficacious.
The company will report initial efficacy data this year, which will be a huge step in proving the concept of PROTAC protein degraders as drugs.
Degradation of proteins has a major therapeutic promise: PROTAC protein degraders can remove almost all of a target protein, including mechanisms of oncology resistance where disease-causing proteins are over-produced. Across a wide range of clinical fields, from oncology and neurodegenerative diseases to cardiovascular and gynecological diseases, targeted protein degradation may be used.